2026 Medical Utilization Forecasts Support BTIG's Bullish View on LifeStance (LFST)

LifeStance Health Group (NASDAQ:LFST) is one of the most promising mid-cap healthcare stocks under $50.

On December 12, BTIG analyst David Larsen reiterated his bullish stance on LifeStance Health Group (NASDAQ:LFST). The analyst rated the stock as Buy and raised the price target from $9 to $10 a share. As per Larsen’s forecasts, the stock offers a highly impressive upside potential of around 42% to investors.

The analyst anticipates strong medical utilization trends in 2026. He attributed such trends to a highly favorable labor market, along with a spike in demand for medical oncology, mental health services, and specialty medications. He also pointed out that such demand could create further space in the market for new medications, which would benefit LifeStance Health Group (NASDAQ:LFST).

The stock has a consensus 1-year average price target of $9, which results in an upside potential of 27.7% from the current level. As of December 19 closing, the forecasts remain strong for LifeStance Health Group (NASDAQ:LFST). The stock has been covered by seven analysts, all of whom have given Buy calls.

LifeStance Health Group (NASDAQ:LFST) is an outpatient health service provider that offers in-person and telehealth services to individuals with mental health problems. Their service offerings include ketamine therapies, psychiatry, and other relevant behavioral health services.

While we acknowledge the potential of LFST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.